Abstract: This invention relates to methods for preparing a sodium-glucose transporter 2 (SGLT2) inhibitor, a cocrytalline SGLT2 and (S)-5-oxopyrrolidine-2-carboxylic acid (L-PGA) complex, and intermediates useful in the preparation of the said SGLT2 inhibitor.

Abstract: This invention relates to methods for preparing a sodium-glucose transporter 2 (SGLT2) inhibitor, a cocrytalline SGLT2 and (S)-5-oxopyrrolidine-2-carboxylic acid (L-PGA) complex, and intermediates useful in the preparation of the said SGLT2 inhibitor.

Abstract: The present principles consider stochastic bandits with side observations, a model that accounts for both the exploration/exploitation dilemma and relationships between arms. In this setting, after pulling an arm i, the decision maker also observes the rewards for some other actions related to i. The present principles provide a method and a system for efficiently leveraging additional information based on the responses provided by other users connected to the user via a computerized social network and derive new bounds improving on standard regret guarantees. We will see that this model is suited to content recommendation in social networks, where users' reactions may be endorsed or not by their friends.

Abstract: A method performed by a recommender system to recommend items to a new user includes calculating reward estimates from multiple multi-armed bandit models of a user and her social network friends. The new user's social network friends have multi-armed bandit models that are well established. The mixed multi-armed bandit estimates are processed to select the arm that maximizes the estimated reward to the new user. The multi-armed bandit arm of the greatest reward estimate is played and the new user responds by providing feedback so that the new user's multi-armed bandit model is updated as time progresses.

Abstract: The present invention relates to novel benzyl(idene)-lactam derivatives, compounds of the formula I wherein R1 is a group of the formula G1 or G2 depicted below, wherein R1, R3, R6, R13 X, a, n and m are as defined herein, their pharmaceutically acceptable salts, and pharmaceutical compositions which include selective antagonists, inverse agonists and partial agonists of serotonin 1 (5-HT1) receptors, specifically, of one or both of the 5-HT1A and 5-HT1B receptors. The compounds of the invention are useful in treating or preventing depression, anxiety, obsessive compulsive disorder (OCD) and other disorders for which a 5-HT1 agonist or antagonist is indicated and have reduced potential for cardiac side effects, in particular QTc prolongation.

Abstract: Methods for the preparation of N-arylated oxazolidinone compounds via a copper catalyzed cross coupling reaction are disclosed.

Abstract: Methods for the preparation of N-arylated oxazolidinone compounds via a copper catalyzed cross coupling reaction are disclosed.

Abstract: The invention relates to processes for preparing a compound of the formula (V) and alkyl boronic esters thereof wherein R1 is attached at the 2 or 3 position of the benzene ring, R2 is attached at the 5 or 6 position, and R1, R2 and G are as defined herein. Said compound is a key synthetic intermediate in the preparation of 2-amino-6-(substituted-4-phenoxy)-substituted-pyridines useful as nitric oxide synthase (NOS) inhibitors in a mammal.

Abstract: The present invention relates to novel benzyl(idene)-lactam derivatives, compounds of the formula I wherein R1 is a group of the formula G1 or G2 depicted below, wherein R1, R3, R6, R13 X, a, n and m are as defined herein, their pharmaceutically acceptable salts, and pharmaceutical compositions which include selective antagonists, inverse agonists and partial agonists of serotonin 1 (5-HT1) receptors, specifically, of one or both of the 5-HT1A and 5-HT1B receptors. The compounds of the invention are useful in treating or preventing depression, anxiety, obsessive compulsive disorder (OCD) and other disorders for which a 5-HT1 agonist or antagonist is indicated and have reduced potential for cardiac side effects, in particular QTc prolongation.

Abstract: The invention relates to an axial compressor stator for a gas turbine, the stator having a rigid, external, annular frame and axially juxtaposed rings configured within the frame and bearing annuli of stationary vanes. The rings are defined by arcuate segments affixed to the frame. The inside walls of the arcuate segments externally define the aerodynamic conduit for the compressed gaseous fluid. The arcuate segments are brazed segments that include a honeycomb component sandwiched between an inner sheetmetal bounding the aerodynamic conduit and an outer sheetmetal. The outer sheetmetal solely connects the arcuate segments to the frame.

Abstract: The invention provides a new process for the preparation of compounds of formula (XI): 1

Abstract: Methods for the preparation of N-arylated oxazolidinone compounds via a copper catalyzed cross coupling reaction are disclosed.

Abstract: The invention relates to a convergent process for preparing a compound of the formula (V), wherein R1 is attached at the 2 or 3 position of the benzene ring, R2 is attached at the 5 or 6 position and R1, R2 and G are as defined herein, in which an aryl boronic acid is coupled with an amine protected halo-substituted-2-aminopyridine using a palladium coupling agent. Compounds of formula V are useful as nitric oxide synthase (NOS) inhibitors in a mammal.

Abstract: The invention relates to an axial compressor stator for a gas turbine, said stator comprising a rigid, external, annular frame (2), furthermore axially juxtaposed rings (4a, 4b, 4c) configured within the frame (2) and bearing annuli of stationary vanes (5), said rings being constituted by arcuate segments (7) affixed to the frame, the inside walls of said arcuate segments externally defining the aerodynamic conduit for the compressed gaseous fluid, and this invention is characterized in that the arcuate segments (2) are brazed segments consisting of a honeycomb component (8) sandwiched between an inner sheetmetal (10) bounding the aerodynamic conduit and an outer sheetmetal (9), and in that the connection to the frame (2) is solely implemented by the outer sheetmetal (9).

Abstract: The invention is a process for producing haloalkyl pyrimidines as intermediates in the production of benzimidazole and/or pyridylimidazole derivatives having high selectivity and/or high affinity to the benzodiazepine site of GABAA receptors.

Abstract: The invention relates to processes for preparing a compound of the formula (V) 1

Abstract: The invention relates to processes for preparing a compound of the formula 1

Abstract: This invention provides a compound of the following formula: or the pharmaceutically acceptable salts thereof wherein Z is OH, C1-6 alkoxy, —NR2R3 or heterocycle; Q is selected from the following: (a) an optionally substituted phenyl, (b) an optionally substituted 6-membered monocyclic aromatic group containing one, two, three or four nitrogen atom(s), (c) an optionally substituted 5-membered monocyclic aromatic group containing one heteroatom selected from O, S and N and optionally containing one, two or three nitrogen atom(s) in addition to said heteroatom, (d) an optionally substituted C3-7 cycloalkyl and (e) an optionally substituted benzo-fuzed heterocycle; R1 is hydrogen, C1-4 alkyl or halo; R2 and R3 are independently hydrogen, OH, C1-4 alkoxy, C1-4 alkyl or C1-4 alkyl substituted with halo, OH, C1-4 alkoxy or CN; X is independently selected from H, halo, C1-4 alkyl, halo-substituted C1-4 alkyl, OH, C1-4 alkoxy, halo-substituted C1-4 alkoxy, C1-4 alkylthio, NO2, NH2, di-(C1-4 al

Abstract: The present invention relates to optically active 3-[(2-piperazinylphenyl)methyl]-1-[4(trifluoromethylphenyl]-2-pyrrolidinones and pharmaceutically acceptable salts thereof, to processes for their preparation, to isotopically-labeled analogs thereof, to pharmaceutical compositions comprising them and to their medicinal use as selective antagonists of the 5-HT1D rector. The compounds of the invention are useful in treating depression, obsessive-compulsive disorder (OCD) and diseases, disorders or conditions for which a 5-HT1D receptor selective antagonist is therapeutically indicated.